Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:39 2022-08-08 am EDT
53.12 EUR   +0.04%
04:02pGalapagos receives transparency notification from FMR LLC
GL
04:01pGalapagos receives transparency notification from FMR LLC
AQ
08:02aRBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about GALAPAGOS NV
04:02pGalapagos receives transparency notification from FMR LLC
GL
04:01pGalapagos receives transparency notification from FMR LLC
AQ
08:02aRBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
06/22Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
MT
06/21Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
MT
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
More most relevant news
All news about GALAPAGOS NV
04:02pGalapagos receives transparency notification from FMR LLC
GL
04:01pGalapagos receives transparency notification from FMR LLC
AQ
08:02aRBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
More news
News in other languages on GALAPAGOS NV
04:17pFMR groter in Galapagos
04:02pGalapagos ontvangt transparantieverklaring van FMR LLC
04:02pGalapagos ontvangt transparantieverklaring van FMR LLC
08/05Galapagos réduit sa perte au 2e trimestre et réduit son revenu net
08/05Sterk kwartaal voor Jyseleca van Galapagos
08/04Galapagos verhoogt verwachte cashburn
08/04Eerste belangrijke stappen in heropbouw van pijplijn en sterke commerciële vooruitgang ..
08/04Eerste belangrijke stappen in heropbouw van pijplijn en sterke commerciële vooruitgang ..
08/04Galapagos NV annonce ses résultats pour le semestre se terminant le 30 juin 2022
07/25ACTUALIZACIÓN DE LAS FUERTES VARIACI : La adquisición de Bobst, Eutelsat se sale de la órb..
More news
Analyst Recommendations on GALAPAGOS NV
08:02aRBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
07/15Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
05/09RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
02/28RBC Cuts Price Target on Galapagos to $60 From $63, Maintains Sector Perform Rating
MT
01/28Bryan Garnier Double Upgrades Galapagos NV to Buy From Sell, Lowers PT to 65 Euros From..
MT
More recommendations
Press releases
04:02pGalapagos receives transparency notification from FMR LLC
GL
04:01pGalapagos receives transparency notification from FMR LLC
AQ
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
More press releases
Official Publications
06/20Share buyback 
06/20Share buyback 
06/01Crossing thresholds 
06/01Crossing thresholds 
05/06Press Release 
05/051st quarter report 
Upcoming event on GALAPAGOS NV
09/08/22Citi BioPharma Conference
Upcoming sector events
10/26/22IQVIA HOLDINGS INC. : Q3 2022 Earnings Release (Projected)
10/27/22ALNYLAM PHARMACEUTICALS, INC. : Q3 2022 Earnings Release (Projected)
10/27/22SEAGEN INC. : Q3 2022 Earnings Release (Projected)
11/03/22MODERNA, INC. : Q3 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research